M. Kraus & CO Amgen Inc Transaction History

M. Kraus & CO

$309 Million
Q3 2024

A detailed history of M. Kraus & CO transactions in Amgen Inc stock. As of the latest transaction made, M. Kraus & CO holds 3,569 shares of AMGN stock, worth $1.05 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

3,569

Previous 3,629 1.65%

Holding current value

$1.05 Million

Previous $1.13 Million 1.41%

% of portfolio

0.37%

Previous 0.38%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	SELL	$309.38 - $337.38 $18,562 - $20,242	-60 Reduced 1.65%	3,569 $1.15 Million
Q2 2024 Jul 10, 2024	SELL	$262.75 - $319.31 $2,627 - $3,193	-10 Reduced 0.27%	3,629 $1.13 Million
Q4 2023 Jan 10, 2024	SELL	$255.7 - $288.46 $3,068 - $3,461	-12 Reduced 0.33%	3,639 $1.05 Million
Q3 2023 Oct 16, 2023	SELL	$218.65 - $271.46 $5,466 - $6,786	-25 Reduced 0.68%	3,651 $981,000
Q2 2023 Jul 14, 2023	SELL	$214.27 - $253.37 $32,354 - $38,258	-151 Reduced 3.95%	3,676 $816,000
Q1 2023 Apr 18, 2023	SELL	$225.79 - $275.2 $677 - $825	-3 Reduced 0.08%	3,827 $925,000
Q4 2022 Jan 25, 2023	SELL	$229.03 - $291.01 $4,351 - $5,529	-19 Reduced 0.49%	3,830 $0
Q3 2022 Oct 27, 2022	BUY	$224.46 - $253.15 $46,687 - $52,655	208 Added 5.71%	3,849 $868,000
Q2 2022 Jul 15, 2022	SELL	$230.71 - $256.74 $461 - $513	-2 Reduced 0.05%	3,641 $886,000
Q1 2022 Apr 28, 2022	BUY	$219.27 - $242.57 $798,800 - $883,682	3,643 New	3,643 $881,000
Q4 2017 Jan 18, 2018	SELL	$168.79 - $188.59 $437,334 - $488,636	-2,591 Closed	0 $0
Q3 2017 Oct 17, 2017	BUY	$167.29 - $191.0 $433,448 - $494,881	2,591	2,591 $483,000

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M. Kraus & CO, based on Form 13F filings with the SEC.

News

Stay updated on M. Kraus & CO with notifications on news.

Account